Zentalis prices 23 million-share follow-on offering at $3.5 per share
ZNTL•Use of proceeds
Zentalis said it intends to use the proceeds to fund development of azenosertib, manufacturing, companion diagnostics and general corporate purposes.
Closing timing and underwriter option
The deal is expected to close on Aug. 17, 2026, subject to customary closing conditions.
The underwriters have a 30-day option to buy up to 3,450,000 additional shares at the offering price.
Offering priced and expected proceeds
Zentalis priced an underwritten public offering of 23,000,000 common shares at $3.50 each.
Gross proceeds are expected to be about $80.5 million, before underwriting discounts, commissions and offering expenses.
